Details for: MEGA FORTE TAB


Product description

Product name: MEGA FORTE TAB

Company name: CARMARAN LTÉE

DIN: 00447269

Status: Cancelled Post Market

Status date: 1996-09-09

Active ingredient(s) Strength
ASCORBIC ACID 100 MG / TAB
BIOTIN 10 MCG / TAB
CALCIUM D-PANTOTHENATE 5.4 MG / TAB
CALCIUM PHOSPHATE (TRIBASIC) 328 MG / TAB
CHOLINE BITARTRATE 15 MG / TAB
CUPRIC SULFATE 4 MG / TAB
D-ALPHA TOCOPHERYL ACETATE 10 UNIT / TAB
FERROUS FUMARATE 47 MG / TAB
FOLIC ACID .05 MG / TAB
INOSITOL 15 MG / TAB
MAGNESIUM OXIDE 83 MG / TAB
NICOTINAMIDE 20 MG / TAB
POTASSIUM IODIDE .14 MG / TAB
PYRIDOXINE HYDROCHLORIDE 2.5 MG / TAB
RETINOL PALMITATE 10000 UNIT / TAB
THIAMINE MONONITRATE 4.5 MG / TAB
VITAMIN B12 5 MCG / TAB
VITAMIN B2 2.5 MG / TAB
VITAMIN D 400 UNIT / TAB

Resources

Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.

For consumers
Resource Description
Report a side effect

Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine.

All suspected side effects should be reported, especially those that are:

  • Unexpected, regardless of their severity, i.e., not consistent with product information or labelling; or
  • Serious, whether expected or not, i.e., that requires being admitted to the hospital, lengthened hospital stay, causes a birth defect, disability, is life-threatening or results in death;
  • Reactions to recently marketed health products (on the market for less than five years), regardless of their nature or severity.

For health care professionals
Resource Description
Report a serious adverse drug reaction (for hospitals)

Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital.

This regulatory requirement only applies to hospitals.

For researchers
Resource Description
Search Clinical Information After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.
All resources
Resource Description
Search Clinical Information After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.
Report a side effect

Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine.

All suspected side effects should be reported, especially those that are:

  • Unexpected, regardless of their severity, i.e., not consistent with product information or labelling; or
  • Serious, whether expected or not, i.e., that requires being admitted to the hospital, lengthened hospital stay, causes a birth defect, disability, is life-threatening or results in death;
  • Reactions to recently marketed health products (on the market for less than five years), regardless of their nature or severity.

Report a serious adverse drug reaction (for hospitals)

Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital.

This regulatory requirement only applies to hospitals.

Resource Description
Report a side effect

Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine.

All suspected side effects should be reported, especially those that are:

  • Unexpected, regardless of their severity, i.e., not consistent with product information or labelling; or
  • Serious, whether expected or not, i.e., that requires being admitted to the hospital, lengthened hospital stay, causes a birth defect, disability, is life-threatening or results in death;
  • Reactions to recently marketed health products (on the market for less than five years), regardless of their nature or severity.